COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth
Zomedica Corp. reports record revenue growth in Q1 2025, driven by strong performance of PulseVet® and TRUFORMA® products. International sales up 32% -
-
-
COMMUNIQUÉ DE PRESSE
Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy
Zomedica Corp. launches Equine Asthma Clinical Registry using PulseVet shock wave therapy to offer non-drug treatment alternative for horses; aims to improve patient care with real-world clinical evidence -
-
-
